Osman Alaa A M, Seres-Bokor Adrienn, Ducza Eszter
Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, H-6720 Szeged, Hungary.
Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, H-6720 Szeged, Hungary.
J Diabetes Complications. 2025 Feb;39(2):108941. doi: 10.1016/j.jdiacomp.2024.108941. Epub 2024 Dec 10.
Type 2 diabetes is a chronic disease requiring comprehensive pharmacological and non-pharmacological interventions to slow its progression and prevent or delay its micro- and macrovascular complications. Oxidative stress contributes to the development and progression of type 2 diabetes as well as to the development of its complications through several mechanisms. Therefore, therapeutic targeting of oxidative stress could aid in managing this disease and its complications. In our study, we have collected information on the most frequently used antidiabetic drugs (metformin, glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors) in the EU and the USA based on their antioxidant effects. Based on our results, we can conclude that the antioxidant effects of the investigated antidiabetics may contribute significantly to the management of the disease and its complications and may open new therapeutic perspectives in their prevention.
2型糖尿病是一种慢性疾病，需要综合的药物和非药物干预措施来减缓其进展，并预防或延缓其微血管和大血管并发症。氧化应激通过多种机制促进2型糖尿病的发生和发展以及其并发症的出现。因此，针对氧化应激进行治疗可能有助于控制这种疾病及其并发症。在我们的研究中，我们基于其抗氧化作用收集了欧盟和美国最常用的抗糖尿病药物（二甲双胍、胰高血糖素样肽1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂）的相关信息。根据我们的研究结果，我们可以得出结论，所研究的抗糖尿病药物的抗氧化作用可能对该疾病及其并发症的控制有显著贡献，并可能为其预防开辟新的治疗前景。
